Analysis of fat necrosis after adjuvant high-dose-rate interstitial brachytherapy for early stage breast cancer

被引:28
|
作者
Garsa, Adam A. [1 ]
Ferraro, Daniel J. [1 ]
DeWees, Todd [1 ]
Margenthaler, Julie A. [2 ]
Naughton, Michael [3 ]
Aft, Rebecca [3 ,4 ]
Gillanders, William B. [3 ]
Eberlein, Timothy [3 ]
Matesa, Melissa A. [1 ]
Zoberi, Imran [1 ]
机构
[1] Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Radiat Oncol,Siteman Canc Ctr, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Surg,Siteman Canc Ctr, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med,Siteman Canc Ctr, St Louis, MO 63110 USA
[4] John Cochran Vet Hosp, Dept Surg, St Louis, MO USA
关键词
Breast cancer; Brachytherapy; Fat necrosis; Cosmesis; Partial breast; RADIATION-THERAPY; RANDOMIZED-TRIAL; IRRADIATION; TOXICITY; CARCINOMA; LUMPECTOMY; COSMESIS;
D O I
10.1016/j.brachy.2012.04.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: To report the incidence and potential predictors of fat necrosis in women with early stage breast cancer treated with adjuvant high-dose-rate (HDR) multicatheter interstitial brachytherapy. METHODS AND MATERIALS: Between 2003 and 2010, 238 treated breasts in 236 women were treated with accelerated partial breast irradiation using HDR interstitial brachytherapy. Selection criteria included patients with Tis-T2 tumors measuring <= 3 cm, without nodal involvement, who underwent breast-conserving surgery. Ninety-nine percent of treatments were to a total dose of 34 Gy. The presence and severity of fat necrosis were prospectively recorded during followup. Cosmesis was qualitatively scored in all patients. Cosmesis was quantitatively measured via the percentage breast retraction assessment in 151 cases. RESULTS: Median followup was 56 months. The crude rate of fat necrosis was 17.6%. The rate of symptomatic fat necrosis was 10.1%. In univariate analysis, acute breast infection and anthracycline-based chemotherapy, number of catheters, volume encompassed by the prescription isodose, volume encompassed by the 150% isodose (V-150), volume encompassed by the 200% isodose, and integrated. reference air kerma were significantly associated with fat necrosis. There was significant collinearity between the brachytherapy-related factors; of these, V-150 was most predictive. In multivariate analysis, only V-150 was significantly associated with fat necrosis. At 3 years, patients with fat necrosis were more likely to have a fair or poor cosmetic outcome and a larger percentage breast retraction assessment. CONCLUSIONS. Mammary fat necrosis is a common adverse event after breast-conserving surgery and HDR interstitial brachytherapy. Fat necrosis is associated with worse qualitative and quantitative cosmetic outcomes Minimizing exposure volumes, such as V-150, may decrease the incidence of fat necrosis and improve cosmesis. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 50 条
  • [41] High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on the consecutive 12 patients and review of the literature
    Vavassori, Andrea
    Gherardi, Federica
    Colangione, Sarah Pia
    Fodor, Cristiana
    Cattani, Federica
    Lazzari, Roberta
    Calabrese, Luca
    Bruschini, Roberto
    Alterio, Daniela
    Jereczek-Fossa, Barbara Alicja
    Orecchia, Roberto
    [J]. TUMORI JOURNAL, 2012, 98 (04): : 471 - 477
  • [42] High-dose-rate interstitial brachytherapy for the treatment of penile carcinoma
    Petera, J
    Odrázka, K
    Zouhar, M
    Bedrosová, J
    Dolezel, M
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 (02) : 123 - 125
  • [43] Perioperative interstitial high-dose-rate brachytherapy for keloids scar
    Barragan, Victoria Vera
    Garcia, Ana Isabel Alonso
    Garcia, Jose Fernandez
    Marin, Marta De Juan
    Pena Vivas, Johanna del Carmen
    Rijo, German Juan
    [J]. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (01) : 29 - 34
  • [44] Experience in multicatheter interstitial high-dose-rate breast brachytherapy: dose-volume histogram analysis of the first results
    Demianovich, Alena
    Sanin, Dmitriy
    Martynova, Valeriya
    Borysheva, Natalia
    Obuhov, Aleksandr
    Aminov, Gamzat
    Gulidov, Igor
    Mardyntsky, Yuriy
    Kiseleva, Marina
    Ivanov, Sergey
    Kaprin, Andrey
    [J]. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (04) : 349 - 355
  • [45] Interstitial high dose rate (HDR) brachytherapy alone for early stage prostate cancer.
    Anderson, P
    Mark, R
    Neumann, T
    Vallabhan, G
    Nair, M
    Akins, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 435S - 435S
  • [46] Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients
    Folkert, Michael R.
    Cohen, Gil'ad N.
    Wu, Abraham J.
    Gerdes, Hans
    Schattner, Mark A.
    Markowitz, Arnold J.
    Ludwig, Emmy
    Ilson, David H.
    Bains, Manjit S.
    Zelefsky, Michael J.
    Goodman, Karyn A.
    [J]. BRACHYTHERAPY, 2013, 12 (05) : 463 - 470
  • [47] High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer
    Nguyen, TV
    Petereit, DG
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 71 (02) : 196 - 203
  • [48] Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer
    Petera, Jiri
    Sirak, Igor
    Tucek, Lubos
    Hodek, Miroslav
    Paluska, Petr
    Kasaova, Linda
    Paulikova, Simona
    Vosmik, Milan
    Dolezalova, Helena
    Cvanova, Michaela
    Halamka, Magdalena
    Laco, Jan
    [J]. PERSONALIZED MEDICINE, 2012, 9 (08) : 879 - 887
  • [49] Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma
    Özyar, E
    Yildz, F
    Akyol, FH
    Atahan, IL
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01): : 101 - 108
  • [50] TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer
    Perera, F
    Chisela, F
    Stitt, L
    Engel, J
    Venkatesan, V
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (05): : 1283 - 1290